Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/128421
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ebert, L.M. | - |
dc.contributor.author | MacRaild, S.E. | - |
dc.contributor.author | Zanker, D. | - |
dc.contributor.author | Davis, I.D. | - |
dc.contributor.author | Cebon, J. | - |
dc.contributor.author | Chen, W. | - |
dc.contributor.editor | Unutmaz, D. | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | PLoS One, 2012; 7(10):e48424-1-e48424-10 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2440/128421 | - |
dc.description.abstract | Cancer vaccines are designed to expand tumor antigen-specific T cells with effector function. However, they may also inadvertently expand regulatory T cells (Treg), which could seriously hamper clinical efficacy. To address this possibility, we developed a novel assay to detect antigen-specific Treg based on down-regulation of surface CD3 following TCR engagement, and used this approach to screen for Treg specific to the NY-ESO-1 tumor antigen in melanoma patients treated with the NY-ESO-1/ISCOMATRIX™ cancer vaccine. All patients tested had Treg (CD25(bright) FoxP3(+) CD127(neg)) specific for at least one NY-ESO-1 epitope in the blood. Strikingly, comparison with pre-treatment samples revealed that many of these responses were induced or boosted by vaccination. The most frequently detected response was toward the HLA-DP4-restricted NY-ESO-1(157-170) epitope, which is also recognized by effector T cells. Notably, functional Treg specific for an HLA-DR-restricted epitope within the NY-ESO-1(115-132) peptide were also identified at high frequency in tumor tissue, suggesting that NY-ESO-1-specific Treg may suppress local anti-tumor immune responses. Together, our data provide compelling evidence for the ability of a cancer vaccine to expand tumor antigen-specific Treg in the setting of advanced cancer, a finding which should be given serious consideration in the design of future cancer vaccine clinical trials. | - |
dc.description.statementofresponsibility | Lisa M. Ebert, Sarah E. MacRaild, Damien Zanker, Ian D. Davis, Jonathan Cebon, Weisan Chen | - |
dc.language.iso | en | - |
dc.publisher | Public Library Science | - |
dc.rights | © 2012 Ebert et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | - |
dc.source.uri | http://dx.doi.org/10.1371/journal.pone.0048424 | - |
dc.subject | Leukocytes, Mononuclear | - |
dc.subject | Cells, Cultured | - |
dc.subject | Humans | - |
dc.subject | Melanoma | - |
dc.subject | Cancer Vaccines | - |
dc.subject | Epitopes | - |
dc.subject | Flow Cytometry | - |
dc.subject | T-Lymphocytes, Regulatory | - |
dc.title | A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1371/journal.pone.0048424 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/433608 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Ebert, L.M. [0000-0002-8041-9666] | - |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_128421.pdf | Published version | 1.47 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.